| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4251345 | Seminars in Nuclear Medicine | 2011 | 5 Pages |
Abstract
Despite early reports of excellent diagnostic characteristics of [131I]/[123I]-metaiodobenzylguanidine (MIBG) in the evaluation of pheochromocytomas/paragangliomas (PHEOs/PGLs) or medullary thyroid cancer as experience with it was accumulated, the sensitivity dropped. Nevertheless, this modality is still useful in the diagnostic work-up of PHEOs/PGLs because it is widely available, and in case of positive scans it might indicate patients who are potential candidates for [131I]MIBG therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Ioannis Ilias, Chaitanya Divgi, Karel Pacak,